In a landmark step towards protecting the most vulnerable from one of the world’s deadliest diseases, the first malaria treatment specifically designed for newborns and young babies has been granted approval for use. 

The new formulation, known as Coartem Baby (or Riamet Baby in some regions), is expected to launch across several African countries within weeks.

Closing the treatment gap
Until now, infants under 4.5kg (approximately 10 pounds) were treated with modified dosages of medications meant for older children—an approach that risked overdose due to babies’ underdeveloped liver function and unique metabolic profiles. Health experts have long called this a critical "treatment gap."

Swiss pharmaceutical company Novartis, in partnership with the Medicines for Malaria Venture (MMV), developed the infant-specific medicine with support from global health institutions and eight African nations. The therapy is set to be distributed largely on a not-for-profit basis.

Voices from the frontlines
“This is a major moment in global health,” said Vas Narasimhan, CEO of Novartis. “After decades of relentless work against malaria, we’re proud to deliver a solution for the smallest and most vulnerable patients.”

Martin Fitchet, CEO of MMV, emphasized the gravity: “Malaria kills hundreds of thousands every year—three-quarters of them young children. Now, at last, we have a safe, optimized treatment for newborns who were previously left behind.”

The stakes are high
In 2023, malaria was responsible for approximately 597,000 deaths, with over 75% of fatalities occurring in children under five—primarily in Africa. The need for targeted treatment is particularly urgent for babies with conditions like sickle cell disease, who face higher risks due to compromised immunity.

A hopeful step forward
Public health experts hail this development as a potential lifesaver. Dr. Marvelle Brown of the University of Hertfordshire called it a “game-changer,” noting that equitable access through not-for-profit distribution could significantly reduce child mortality in malaria-endemic regions.

This approval marks not just a scientific win, but a humanitarian triumph.

Source: BBC

SMS/